ACTR-67. PLASMA AND TUMOR PHARMACOKINETICS OF RIBOCICLIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
Sign Up to like & getrecommendations! Published in 2017 at "Neuro-oncology"
DOI: 10.1093/neuonc/nox168.054
Abstract: BACKGROUND CDK4/6-dependent cell-cycle regulation is disrupted in 78% of glioblastoma (GBM) patients and novel CDK4/6 inhibitors have shown anti-tumor activity in animal models. To explore the utility of ribociclib, a selective CDK4/6-inhibitor, in treating recurrent… read more here.
Keywords: ribociclib patients; tumor pharmacokinetics; actr plasma; plasma tumor ... See more keywords
Plasma Tumor Mutation Burden and Response to Pembrolizumab—Letter
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-0903
Abstract: Predictive biomarkers are critical for patient selection in immune checkpoint inhibitor (ICI) therapy. However, the term “predictive” are often confused with “prognostic,” leading to inappropriate treatment choice in clinical practice and research. We read with… read more here.
Keywords: burden response; tumor mutation; mutation burden; pembrolizumab letter ... See more keywords
Plasma Tumor Mutation Burden and Response to Pembrolizumab—Response
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-1073
Abstract: We have carefully reviewed the letter from Li and colleagues and believe that there were misunderstandings of the results and interpretation of the findings, which we would like to take the opportunity to clarify. We… read more here.
Keywords: burden response; response; tumor mutation; mutation burden ... See more keywords
Abstract LB-249: Examination of analytical factors impacting concordance of plasma-tumor testing by next-generation sequencing (NGS)
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-lb-249
Abstract: The increased usage of circulating tumor DNA (ctDNA) sequencing for oncology clinical research demonstrates a critical need for sensitive and specific testing. While we have observed a high degree of concordance between single tumor mutations… read more here.
Keywords: concordance plasma; concordance; examination analytical; plasma tumor ... See more keywords
Tissue and plasma tumor mutation burden (TMB) as predictive biomarkers in the CO.26 trial of durvalumab + tremelimumab (D+T) versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.3_suppl.61
Abstract: 61Background: Pembrolizumab was recently granted tissue agnostic FDA accelerated approval for metastatic cancers with TMB≥10 mut/Mb. However, limited data supports immunotherapy in microsatellite s... read more here.
Keywords: burden tmb; tumor mutation; mutation burden; tissue ... See more keywords